The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will...

Descripción completa

Detalles Bibliográficos
Autores principales: Castrellon, Aurelio Bartolome, Pidhorecky, Ihor, Valero, Vicente, Raez, Luis Estuardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365000/
https://www.ncbi.nlm.nih.gov/pubmed/28382189
http://dx.doi.org/10.4081/oncol.2017.324
_version_ 1782517438520229888
author Castrellon, Aurelio Bartolome
Pidhorecky, Ihor
Valero, Vicente
Raez, Luis Estuardo
author_facet Castrellon, Aurelio Bartolome
Pidhorecky, Ihor
Valero, Vicente
Raez, Luis Estuardo
author_sort Castrellon, Aurelio Bartolome
collection PubMed
description Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.
format Online
Article
Text
id pubmed-5365000
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-53650002017-04-05 The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer Castrellon, Aurelio Bartolome Pidhorecky, Ihor Valero, Vicente Raez, Luis Estuardo Oncol Rev Review Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT. PAGEPress Publications, Pavia, Italy 2017-03-17 /pmc/articles/PMC5365000/ /pubmed/28382189 http://dx.doi.org/10.4081/oncol.2017.324 Text en ©Copyright A.B. Castrellon et al. 2017 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Castrellon, Aurelio Bartolome
Pidhorecky, Ihor
Valero, Vicente
Raez, Luis Estuardo
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title_full The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title_fullStr The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title_full_unstemmed The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title_short The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
title_sort role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365000/
https://www.ncbi.nlm.nih.gov/pubmed/28382189
http://dx.doi.org/10.4081/oncol.2017.324
work_keys_str_mv AT castrellonaureliobartolome theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT pidhoreckyihor theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT valerovicente theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT raezluisestuardo theroleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT castrellonaureliobartolome roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT pidhoreckyihor roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT valerovicente roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer
AT raezluisestuardo roleofcarboplatinintheneoadjuvantchemotherapytreatmentoftriplenegativebreastcancer

Ejemplares similares